Abstract:
The criteria for diagnosis and assessment of therapeutic effects has changed with the rapid development in diagnostic technology and treatment for multiple myeloma (MM). The standardized diagnosis and treatment are the cornerstone of individualized therapy. At present, standardization is lacking in MM diagnosis and treatment in China. In China, serum protein electrophoresis is used but not immunofixation, immunoglubin is used instead of M protein for diagnosis, morphology of the plasma cell is used to determine malignancy of the plasma cell, and some lymphomas are misdiagnosed as MM. The prognostic stratification is overshadowed and the number of patients who received autologous transplantation was much lower compared with other countries. The standardization of the diagnosis and treatment criteria in China will ensure better communication with other countries about MM and promote cooperation.